Articles by Isabel Ryan, MRA Intern


FDA Approves Opzulera for At-Home Therapy for Skin Repigmentation: What this Means for Melanoma Patients with Vitiligo

By Isabel Ryan, MRA Intern | 24 October 2022 In News, Science

On July 18th, the U.S. Food & Drug Administration (FDA) approved the first topically-applied treatment for skin repigmentation for patients with vitiligo after strong results from two Phase 3 trials. Vitiligo, a chronic skin disease, affects 3 in 100 people who have melanoma, categorized as melanoma-associated vitiligo. The approval invites patients with vitiligo, including those with melanoma, to talk with their providers on how Opzelura can serve their skin needs.

Read More

About the Author
Isabel Ryan, MRA Intern


Login

×